Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review

Cancer Treatment Reviews

Volumn 41, Issue 10, 2015, Pages 935-950

  Frederiks, C N ^a   Lam, S W ^a   Guchelaar, H J ^b   Boven, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Docetaxel; Paclitaxel; Pharmacogenetics; Single nucleotide polymorphisms; Toxicity

Indexed keywords

DOCETAXEL; PACLITAXEL; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR A6; MULTIDRUG RESISTANCE PROTEIN; TAXOID; TUBULIN;

ABCB1 GENE; ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; EPHA5 GENE; EPHA6 GENE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHARMACODYNAMICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUBB2A GENE; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; GENETICS; HEMATOLOGIC DISEASE; NEUROTOXICITY SYNDROMES;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEINS; PACLITAXEL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPHA5; RECEPTOR, EPHA6; TAXOIDS; TUBULIN;

EID: 84958900894     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.10.010     Document Type: Review

References (68)

1. De Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel - a review. Anticancer Drugs 2014;25 (5):488-94.
2. Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 2012;13 (16):1979-88.
3. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003;29(5):407-15.
4. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002;11 (1):103-18.
5. Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. Clin Cancer Res 2013;19(17):4570-7.
6. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358 (16):1663-71.
7. Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010;36(1):69-74.
8. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42(1):24-30.
9. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014;40(7):872-82.
10. Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Åvall Lundqvist E, et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104(2):130-7.
11. Hertz DL. Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 2013;14(9):1065-84.
12. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18 (18):5099-109.
13. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, et al. Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009;20(2):272-7.
14. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010;124(2):593-8.
15. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res 2014;20(9):2466-75.
16. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011;130(3):993-1002.
17. Park SB, Kwok JB, Loy CT, Friedlander ML, Lin CSY, Krishnan AV, et al. Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer 2014;14:993.
18. Chew SC, Lim J, Singh O, Chen X, Tan EH, Lee EJ, et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients. Eur J Clin Pharmacol 2014;70(2):155-66.
19. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, et al. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 2013;23(1):29-33.
20. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, et al. Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009;20(4):736-40.
21. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80.
22. Nieuweboer AJM, Smid M, De Graan AJM, Elbouazzaoui S, De Bruijn P, Eskens FALM, et al. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J 2015 [Online].
23. Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 2012;69 (5):1221-7.
24. Awada Z, Haider S, Tfayli A, Bazarbachi A, El-Saghir NS, Salem Z, et al. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. Omics 2013;17 (7):353-67.
25. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11(4):241-6.
26. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012;92(4):467-75.
27. Leandro-García LJ, Inglada-Pérez L, Pita G, Hjerpe E, Leskelä S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 2013;50 (9):599-605.
28. Low SK, Chung S, Takahashi A, Zembutsu H, Mushiroda T, Kubo M, et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci 2013;104 (8):1074-82.
29. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, et al. Genomewide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011;6 (1):132-8.
30. Callens C, Debled M, Delord M, Turbiez-Stalain I, Veyret C, Bièche I, et al. Highthroughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. Breast Cancer Res Treat 2015;153:383-9.
31. Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, et al. Genetic heterogeneity beyond CYP2C8/3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 2014;145(1): 245-54.
32. Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010;10(3):191-9.
33. Uchiyama T, Kanno H, Ishitani K, Fujii H, Ohta H, Matsui H, et al. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol 2012;69(6):1617-24.
34. Nieuweboer AJM, Smid M, De Graan AJM, Elbouazzaoui S, De Bruijn P, Martens JW, et al. Predicting paclitaxel-induced neutropenia using the DMET platform. Pharmacogenomics 2015 [Online].
35. Bosó V, Herrero MJ, Santaballa A, Palomar L, Megias JE, De la Cueva H, et al. SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics 2014;15(15):1845-58.
36. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced nonsmall- cell lung cancer. Ann Oncol 2004;15(8):1194-203.
37. Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 2015;106:86-93.
38. Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ, et al. Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep 2010;23(1):271-8.
39. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009;113(2):264-9.
40. Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 2011;110:199-204.
41. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25(29):4528-35.
42. Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, et al. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 2012;17(3):204-11.
43. Choi JR, Kim JO, Kang DR, Shin JY, Zhang XH, Oh JE, et al. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat 2015;47(3):509-17.
44. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27(21):3540-6.
45. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009;404(2):160-5.
46. Tulsyan S, Chaturvedi P, Kumar Singh A, Agarwal G, Lal P, Agrawal S, et al. Assessment of clinical outcoms in breast cancer patients treated with taxanes: multi-analytical approach. Gene 2014;543:69-75.
47. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008;14(14):4543-9.
48. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxelinduced leukopenia. Cancer Sci 2008;99(5):967-72.
49. Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011;67(7):693-700.
50. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, et al. CYP2C8/3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134(1): 401-10.
51. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, et al. CYP2C8/3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013;24(6):1472-8.
52. Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11(2):121-9.
53. De Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4/22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013;19(12):3316-24.
54. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with earlystage breast cancer. Acta Oncol 2014 [Online].
55. Leandro-García LJ, Leskelä S, Jara C, Gréen H, Åvall-Lundqvist E, Wheeler HE, et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012;18 (16):4441-8.
56. Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8/3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2001;11:113-20.
57. De Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, et al. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 2013;19(18):5210-7.
58. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 2010;15(Suppl. 2):13-8.
59. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11(5):509-13.
60. McWhinney-Glass S, Winham SJ, Hertz DL, Revollo JY, Paul J, He Y, et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013;19(20):5769-76.
61. Lambrechts S, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Smeets D, Debruyne PR, et al. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity in ovarian cancer. BMC Pharmacol Toxicol 2015;16:2.
62. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health 2000;24(3):164-8.
63. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2013;31(11):1405-14.
64. Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol 2007;30(5):507-13.
65. Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol 2011;68 (5):1255-62.
66. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006;12(20 Pt. 1):6094-9.
67. Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, et al. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2009;20(3):481-5.
68. Bergmann TK, Vach W, Feddersen S, Eckhoff L, Gréen H, Herrstedt J, et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 2013;52(4):871-4.